April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Worldwide Experiences With Intravitreal Anti-VEGFs for ROP
Edgard Omar Rodriguez Torres, Sr.; Maria A. Martinez; Hugo Quiroz Mercado; Jose L. Guerrero Naranjo; Wu Wei Chi; Robison V. Paul Chan; Kuo His Kung; Alay S. Banker
Author Affiliations & Notes
  • Edgard Omar Rodriguez Torres, Sr.
    Ophthalmology,
    Asociacion para Evitar la Ceguera en Mexico (APEC), Mexico, Mexico
  • Maria A. Martinez
    Retina,
    Asociacion para Evitar la Ceguera en Mexico (APEC), Mexico, Mexico
  • Hugo Quiroz Mercado
    Retina,
    Asociacion para Evitar la Ceguera en Mexico (APEC), Mexico, Mexico
  • Jose L. Guerrero Naranjo
    Retina,
    Asociacion para Evitar la Ceguera en Mexico (APEC), Mexico, Mexico
  • Wu Wei Chi
    Ophthalmology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
  • Robison V. Paul Chan
    Ophthalmology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York
  • Kuo His Kung
    Ophthalmology, Chang Gung Memorial Hospital - Kaohsiung Medical Center, Kaohsiung, Taiwan
  • Alay S. Banker
    Ophthalmology, Banker′s Retina Clinic and Laser Center, Ahmedabad, India
  • Footnotes
    Commercial Relationships  Edgard Omar Rodriguez Torres, Sr., None; Maria A. Martinez, None; Hugo Quiroz Mercado, None; Jose L. Guerrero Naranjo, None; Wu Wei Chi, None; Robison V. Paul Chan, St. Giles Foundation and from a departmental grant from research to prevent blindness (F); Kuo His Kung, None; Alay S. Banker, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 3125. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Worldwide Experiences With Intravitreal Anti-VEGFs for ROP
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Edgard Omar Rodriguez Torres, Sr., Maria A. Martinez, Hugo Quiroz Mercado, Jose L. Guerrero Naranjo, Wu Wei Chi, Robison V. Paul Chan, Kuo His Kung, Alay S. Banker; Worldwide Experiences With Intravitreal Anti-VEGFs for ROP. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3125.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : To evaluate the efficacy of intravitreal anti-VEGF agents in ROP.

Methods: : Multicentered study of 247 eyes with ROP (stage 3 and 4) treated with intravitreal anti-VEGFs (221, bevacizumab; 16, pegaptanib; 10, ranibizumab), with laser (59 eyes) and without laser (188 eyes). Birth weight and gestational age ranged from 700 to 962 grams and 24-29 weeks, respectively.

Results: : All eyes showed regression of neovascularization and normal vascular growth. Only 4 eyes had transient vitreous hemorrhage, and 10 eyes needed vitrectomy. No systemic adverse events were observed in up to 4 years follow-up.

Conclusions: : Intravitreal anti-VEGF drugs may be safe and effective in the treatment of ROP.

Clinical Trial: : http://www.clinicaltrials.gov NCT00346814

Keywords: retinopathy of prematurity • vascular endothelial growth factor • retinal neovascularization 
© 2011, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept